Results 11 to 20 of about 303,632 (262)

Ruxolitinib Versus Best Available Therapy for Polycythemia Vera Intolerant or Resistant to Hydroxycarbamide in a Randomized Trial

Journal of Clinical Oncology, 2023
PURPOSE Polycythemia vera (PV) is characterized by JAK/STAT activation, thrombotic/hemorrhagic events, systemic symptoms, and disease transformation. In high-risk PV, ruxolitinib controls blood counts and improves symptoms.
C. Harrison, J. Nangalia, R. Boucher, Aimee E Jackson, C. Yap, J. O'Sullivan, Sonia Fox, Isaak Ailts, A. Dueck, H. Geyer, Ruben A. Mesa, W. Dunn, Eugene Nadezhdin, N. Curto-Garcia, A. Green, B. Wilkins, J. Coppell, J. Laurie, M. Garg, J. Ewing, S. Knapper, Josephine Crowe, Frederick Chen, I. Koutsavlis, A. Godfrey, S. Arami, M. Drummond, J. Byrne, F. Clark, Carolyn Mead-Harvey, E. J. Baxter, M. McMullin, A. Mead   +32 more
semanticscholar   +1 more source

Prevalence and diagnostic performance of iron deficiency in polycythemia

Hematology, 2023
Introduction Several observations have shown that patients with polycythemia have iron deficiency. Our objectives were to report the prevalence of iron deficiency and to evaluate the diagnostic performance of serum ferritin in polycythemia vera.Patients ...
Rova Malala Fandresena Randrianarisoa, Herveat Ramanandafy, Alexandre Mania, Hélène Monjanel, Sébastien Trouillier   +4 more
doaj   +1 more source

Ropeginterferon versus Standard Therapy for Low-Risk Patients with Polycythemia Vera.

NEJM Evidence, 2023
Ropeginterferon for Patients with Polycythemia VeraPatients with low-risk polycythemia vera were randomly assigned to receive ropeginterferon alfa-2b and phlebotomy or phlebotomy alone.
T. Barbui, A. Vannucchi, V. De Stefano, A. Carobbio, A. Ghirardi, Greta Carioli, A. Masciulli, E. Rossi, F. Ciceri, M. Bonifacio, A. Iurlo, F. Palandri, G. Benevolo, F. Pane, A. Ricco, G. Carli, M. Caramella, D. Rapezzi, C. Musolino, S. Siragusa, E. Rumi, A. Patriarca, N. Cascavilla, B. Mora, E. Cacciola, C. Mannarelli, G. G. Loscocco, P. Guglielmelli, F. Gesullo, S. Betti, F. Lunghi, L. Scaffidi, C. Bucelli, N. Vianelli, M. Bellini, M. Finazzi, G. Tognoni, A. Rambaldi   +37 more
semanticscholar   +1 more source

JAK2V617F allele burden in polycythemia vera: burden of proof

Blood, 2023
Visual ...
A. Moliterno, H. Kaizer, B. Reeves
semanticscholar   +1 more source

A randomized phase 3 trial of interferon-α vs hydroxyurea in polycythemia vera and essential thrombocythemia

Blood, 2022
Therapy for essential thrombocythemia (ET) and polycythemia vera (PV) is aimed at reducing thrombotic risk through normalizing blood counts. Mascarenhas et al report on a randomized trial of hydroxyurea (HU) vs pegylated interferon α (PEG) in 168 ...
J. Mascarenhas, H. Kosiorek, J. Prchal, A. Rambaldi, Dmitriy Berenzon, A. Yacoub, C. Harrison, M. McMullin, A. Vannucchi, J. Ewing, C. O'Connell, J. Kiladjian, A. Mead, E. Winton, D. Leibowitz, V. De Stefano, M. Arcasoy, C. Kessler, R. Catchatourian, D. Rondelli, R. Silver, A. Bacigalupo, A. Nagler, M. Kremyanskaya, M. Levine, J. A. Arango Ossa, E. McGovern, L. Sandy, M. Salama, V. Najfeld, J. Tripodi, N. Farnoud, A. Penson, R. Weinberg, L. Price, J. Goldberg, R. Marchioli, G. Tognoni, R. Rampal, R. Mesa, A. Dueck, R. Hoffman, T. Barbui   +42 more
semanticscholar   +1 more source

Long-term outcomes of polycythemia vera patients treated with ropeginterferon Alfa-2b

Leukemia, 2022
TO THE EDITOR: Interferon alfa not only restores normal blood cell counts in patients with polycythemia vera (PV) but can diminish the mutant JAK2 V617F allele burden [1 – 3].
J. Kiladjian, C. Klade, P. Georgiev, D. Krochmalczyk, L. Gercheva‐Kyuchukova, M. Egyed, P. Dulíček, Á. Illés, H. Pylypenko, L. Sivcheva, J. Mayer, V. Yablokova, K. Krejcy, V. Empson, H. Hasselbalch, R. Kralovics, H. Gisslinger, Jean-Jacques Pencho Dorota Liana Miklos Petr Arpad Halyna Lylia Kiladjian Georgiev Krochmalczyk Gercheva-Kyuchukov, J. Kiladjian   +18 more
semanticscholar   +1 more source

Neutrophil-to-lymphocyte ratio is a novel predictor of venous thrombosis in polycythemia vera

Blood Cancer Journal, 2022
We investigated the neutrophil-to-lymphocyte ratio (NLR) as a predictor of thrombosis in polycythemia vera (PV). After a median follow-up of 2.51 years, of 1508 PV patients enrolled in the ECLAP study, 82 and 84 developed arterial and venous thrombosis ...
A. Carobbio, A. Vannucchi, V. De Stefano, A. Masciulli, P. Guglielmelli, G. G. Loscocco, F. Ramundo, E. Rossi, Y. Kanthi, A. Tefferi, T. Barbui   +10 more
semanticscholar   +1 more source

Polisitemi Veralı Hastalarda Dinamik Thiol/Disulfit Dengesi ve İskemi Modifiye Albumin Düzeyleri

Düzce Tıp Fakültesi Dergisi, 2021
Aim: Polycythemia vera is a chronic myeloproliferative disease characterized by increased red cell mass and JAK2 mutation positivity. Transformation to myelofibrosis and acute leukemia is possible in patients with polycythemia vera.
Özcan Erel, Hakan Basir, Mustafa Ilgan, Eyüp Naci Tiftik, Mahmut Bakır Koyuncu, Mehmet Ali Uçar, Aydan Akdeniz, Anıl Tombak, Salim Neşelioğlu   +8 more
doaj   +1 more source

Polycythemia vera: historical oversights, diagnostic details, and therapeutic views

Leukemia, 2021
Polycythemia vera (PV) is a relatively indolent myeloid neoplasm with median survival that exceeds 35 years in young patients, but its natural history might be interrupted by thrombotic, fibrotic, or leukemic events, with respective 20-year rates of 26%,
A. Tefferi, A. Vannucchi, T. Barbui
semanticscholar   +1 more source

Polycythemia vera presenting with pulmonary embolism and splenic infarction: a case report

Journal of International Medical Research, 2022
Pulmonary embolism and splenic infarction are rare in patients with polycythemia vera. We herein describe a man in his early 60s whose main symptoms were chest tightness, cough, and sputum expectoration.
Ping Huang, Yuhong Li
doaj   +1 more source